NCT01337518View on ClinicalTrials.gov

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

PHASE1SuspendedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Prostatic Neoplasm
Interventions
DRUG

EZN-4176

EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

SM2 5PT

Institute of Cancer Research, Royal Marsden Hospital, Sutton

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY